News | Proton Therapy | August 06, 2015

Mevion Medical Systems Forming Joint Venture in China

S250 proton therapy system manufacturer secures up to $200 million in financing to expand global presence
 

Mevion Medical Systems, joint venture, China, S250, proton therapy centers

August 6, 2015 — Mevion Medical Systems announced today that it has entered into an investment agreement where up to $200 million will be invested in Mevion to accelerate its worldwide expansion. The investment was led by HOPU Investments, YuanMing Capital, and participated in by other Chinese investors and existing U.S. investors Caxton Alternative Management L.P., ProQuest Investments, Venrock and CHL Medical Partners. Concurrent with the investment, Mevion and the lead investors will form a joint venture in China to produce, sell and service proton therapy systems for the Chinese market. HOPU and YuanMing have extensive experience investing in successful healthcare companies and offer a significant network of healthcare experience in China.

The investment will support an increase in Mevion’s manufacturing capacity and global service capability to support the installation of new proton therapy sites in the United States, China and internationally.

“Proton therapy is an increasingly significant treatment modality for cancer centers around the world, and we see real value in advancing accessibility to this important therapy in China and elsewhere,” said Sunny Li, senior managing director and head of technology investments of HOPU Investments. “We have conducted an extensive industry survey of proton therapy companies. Only one company is commercially proven to have both the best technology and the best economics for healthcare providers and that is Mevion. We wanted to be a part of this success story.”

Yuan Tian and Dr. Tina Yu, partners of YuanMing Capital, stated, “We are very interested in investing in medtech leaders in the U.S. like Mevion, and truly believe that we can help these U.S. companies grow and maximize value in the Chinese market.”

The first Mevion system, which is installed at Barnes-Jewish Hospital in St. Louis, achieved the fastest per-room ramp-up of any proton therapy system, treating its first 100 patients in a single room in just 11 months. That system was followed by the clinical start of the Ackerman Cancer Center (ACC) in Jacksonville, Florida. The system at ACC beat all global patient treatment ramp-up records by reaching a per-room rate of 350 patients per year in less than three months. This treatment rate is comparable to the total number of patients treated each year at costlier four-room legacy systems. And, this spring, Mevion became the first proton therapy manufacturer to open two facilities back-to-back; the system at Robert Wood Johnson University Hospital treated its first patient less than four weeks after the first patient was treated at ACC, further evidence of its breakthrough efficiency.

The Mevion S250 delivers higher-quality, targeted radiation therapy for cancer patients at a fraction of the size and operating costs and with much higher operational efficiency than the legacy proton systems. Its modular design and smaller footprint – a single-room format occupies only 2,000 sq. ft. (180 sq. m) – means that a Mevion S250 can be added to existing cancer facilities in even the most densely populated cities with extreme space constraints, while installations can be scaled to provide multi-room capabilities at large cancer hospitals. And, it is an environmentally friendly system, using less than 10 percent of the energy of legacy systems.

For more information: www.mevion.com

Related Content

MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...